DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Optimization of Tuberculosis Intradermal Skin Test

Information source: Hospices Civils de Lyon
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Volunteers

Intervention: Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative) (Device); medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative) (Device)

Phase: N/A

Status: Recruiting

Sponsored by: Hospices Civils de Lyon

Official(s) and/or principal investigator(s):
Catherine GOUJON, MD, Principal Investigator, Affiliation: Centre Hospitalier Lyon Sud -Hospices Civils de Lyon

Overall contact:
Catherine GOUJON, MD, Phone: +33 478 86 41 25, Email: catherine.goujon@chu-lyon.fr

Summary

The only test available for in vivo diagnosis of tuberculosis is the intradermal injection of tuberculin according to the Mantoux method (also named tuberculosis skin test or PPD skin test).

The tuberculin skin test is based on a delayed-type hypersensitivity skin reaction However, this test needs to be performed by trained personnel, presents problem of reproducibility, and its interpretation is not well standardized (measure in millimeters of skin induration 48 to 72 hours after the PPD skin test).

The new generation BD micro needle used in this study should solve the technical difficulties; intradermal administration of tuberculin could then be made by any personnel.

A non-invasive and objective instrumental method of reading the test will be also tested .

Clinical Details

Official title: Optimization of Tuberculosis Intradermal Skin Test: TB Dermatest WP 3.1

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic

Primary outcome: hypersensitivity reaction to tuberculin measured in millimeters of skin induration by comparing two methods of intradermal injection (Mantoux and BD micro-needle). [Phase 1]

Secondary outcome:

spectroscopy instrumentation(non-invasive and objective method)to measure the PPD reaction

define changes in the cutaneous immune system at various times (7h, 24h and 48 h), induced by intradermal microinjection of tuberculin, by histological, immunohistochemical and molecular analysis

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subject aged 18 years or over

- Tuberculosis skin test (PPD)

- positive : 5mm =

- negative: PPD < 5mm (6 subjects)

- Negative Quantiferon test.

- Legal capacity to consent

- Subject had given written consent before his participation

- Subject accepting to participate in the second phase of the study with skin biopsies

(24 subjects with positive PPD)

- Females of childbearing potential using an effective method of contraception, for at

least 1 month before the beginning of the study and until 1 month after the end of their participation

Exclusion Criteria:

- Known allergy to tuberculin

- History of severe skin reaction to tuberculin with vesicle, ulceration, necrosis

- History of active tuberculosis

- Latent tuberculosis (positive Quantiferon test)

- Contact with a person having or having had active tuberculosis in the previous 3

months

- Chronic disease non-stabilized under treatment

- Immunosuppressive therapy or corticosteroids within 1 month before PPD skin tests

- Non-steroid anti-inflammatory drugs within 1 week before PPD skin tests

- Application on study areas of topical drugs containing corticoids or

immunosuppressants within 1 week before PPD skin test

- Dermatological disease on study area

- Known allergy to local anesthetics

- Wound healing disorders

- Subject in an exclusion period or participating or planning to participate in another

biomedical research

Locations and Contacts

Catherine GOUJON, MD, Phone: +33 478 86 41 25, Email: catherine.goujon@chu-lyon.fr

Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie-Centre Hospitalier Lyon Sud -Hospices Civils de Lyon, Pierre-Bénite 69495, France; Recruiting
Catherine GOUJON, MD, Phone: +33 478 86 41 25, Email: catherine.goujon@chu-lyon.fr
Catherine GOUJON, MD, Principal Investigator
Sophie GRANDE, MD, Sub-Investigator
Additional Information

Starting date: September 2011
Last updated: May 31, 2012

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014